More than Rs 15,360 crore estimated to have been saved due to central government service
The injectable manufacturing company expects the margin pressure to persist due to cost pressures and negative operating leverage.
Company left with low-margin brands in India after selling profitable ones
Domestic brokerage Motilal Oswal has set a price target of Rs 210 for the stock
According to the media reports, Karnataka has directed all drugmakers to test samples of glycerine and propylene glycol and submit a report within seven days.
Centre forms panel to analyse causal relation between deaths and cough syrups
The firm has been in news for supplying contaminated cough syrups to Gambia, which is linked to the deaths of 66 children due to the presence of contaminants
The firm already has manufacturing units in four Indian cities, all of which are focused on the export market
Says Indian Pharmaceutical Alliance's investigation report cleared Dolo-650 maker, Micro Labs, of allegations of bribing doctors with freebies worth Rs 1,000 crore
Sales declining anyway and there is no need to ban because of alleged misuse, say experts
Softbank-backed B2B e-commerce firm Udaan has started delivering stocks to pharmacies four times a day across six cities and plans to scale up the service to other places after six to eight months, the company said on Thursday. The 4X4 delivery service' has been rolled out after a pilot programme and receiving extensive feedback from pharmacies in select cities, which required enhanced delivery capabilities. During the pilot phase, the business witnessed a 45 per cent rise in orders in the select cities. "As part of the new service offering, Udaan will provide medicine delivery to pharmacies every 4-hour with 4 delivery slot options in a day to order medicines across six cities - Kolkata, Jaipur, Indore, Ahmedabad, Bengaluru and Pune. Udaan plans to scale the '4X4 delivery service' to more cities and towns in the next 6-8 months," the company said in a statement. Udaan Business head for Pharma Category Sanjay Sharma said the company will leverage for the convenience and faster ...
Company founded by 4 IIT graduates will use money to expand its presence and for improving technology
First major acquisition by Aman Mehta after taking charge at Torrent Pharma in August
In December 2019 the decision was revised to allow sale of land to private entities as well through a competitive bidding process
The offer for sale is expected to be anywhere between Rs 5000-5500 crore, say sources
SSI Mantra has already been used for 22 complex procedures at Delhi hospital
Analysts expect double-digit growth for pharma major even if Q1 disappointed
Medicines to treat diabetes, HIV, TB, contraceptives, hormonal medicines included in National List of Essential Medicines
The 2022 revision of the NLEM came after seven years. Most drugs that have been now brought into the NLEM include anti-infectives, anti-diabetics, anesthetics, etc
Zenara Pharma on Friday announced the launch of nirmatrelvir and ritonavir tablets in a combination pack to be used as a treatment option for patients with mild-to-moderate symptoms of COVID-19. The company received approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market this product last month, Zenara Pharma said in a statement. The drug will be sold under the brand name 'Paxzen' and is priced at Rs 5,200 per pack containing 20 tablets of nirmatrelvir 150 mg and 10 tablets of ritonavir 100 mg, which is equivalent to one full course of treatment for a patient, it added. It will be manufactured at Zenara's USFDA and EU-approved facility in Hyderabad, the company said. "Our product Paxzen has been proven equivalent to Paxlovid through a bioequivalence study, based on which we have received the approval from the regulatory authorities," Zenara Pharma co-founder and Managing Director, Jagadeesh Babu Rangisetty said. The USFDA had approved Paxlov